DXCM

$DXCM

DexCom, Inc.

Continuous glucose monitoring systems for diabetes management.

Healthcare
$80.19
-2.33 (-2.82%)
Day Range$79.19 - $82.76
Prev Close$82.52

DXCM key facts as of November 14, 2026

Latest AI research report
DXCM Stock: Growth, Valuation and Key Risks (as of November 14, 2026)
StockAlpha report sentiment
Bullish (as of November 14, 2026)
Analyst consensus
Strong Buy (4 Strong Buy, 22 Buy, 3 Hold, 0 Sell, 0 Strong Sell) (as of November 1, 2026)
Analyst price target
$97.85 mean (range $86.00 to $115.00) (as of November 20, 2026)
Sector
Healthcare
Analyst Rating
Strong Buy
26 Buy / 3 Hold / 0 Sell
Price Target
$97.85
22.0% upside
Subscribers
0
Tracking this ticker
Latest Report

Analysis from Nov 13, 2026

BULLISH

DXCM Stock: Growth, Valuation and Key Risks

DexCom’s recent earnings beat, expanding CGM adoption and 11.2% reported revenue growth support a constructive outlook, while competition and valuation remain important counterweights. Here’s what Friday’s price, analyst expectations and upcoming catalysts suggest for DXCM.

Nov 14, 2026

DXCM FAQ

What is StockAlpha's latest view on DXCM?

StockAlpha's latest AI research report on DexCom, Inc. (DXCM), "DXCM Stock: Growth, Valuation and Key Risks", was published on November 14, 2026 and rates the overall sentiment as bullish. DexCom’s recent earnings beat, expanding CGM adoption and 11.2% reported revenue growth support a constructive outlook, while competition and valuation remain important counterweights. Here’s what Friday’s price, analyst expectations and upcoming catalysts suggest for DXCM.

When was the DXCM research last updated?

The most recent DXCM report was published on November 14, 2026.

What do analysts expect for DXCM?

As of November 1, 2026, the analyst consensus on DXCM is Strong Buy (4 Strong Buy, 22 Buy, 3 Hold, 0 Sell, 0 Strong Sell). As of November 20, 2026, the analyst price target is $97.85 mean (range $86.00 to $115.00).

Is this DXCM research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring